The role of the inflammatory cells in breast cancer was validated using for the first time to our knowledge data extracted from the EudraVigilance database that contains reports of inflammatory and immune-related reactions (ADR) of patients under anti-HER2 treatments in the adult unselected population. The gene discussed is ERBB2; the disease is breast carcinoma.